Summer update
The dutch team (Rotterdam and The Hague) is getting ready to include patients after all approvals in place. Thanks to everyone for their effort in making it happen.
In addition, we want to thank the teams in Odense and Stockholm for their recent inclusions.
The community have also acknowledged the need for randomised trials on this topic, with the recently started ATLAS/NOA-29 trial in addition to the US/Canadian G-SUMIT.
New inclusions, new members
We congratulate the team in Helsinki with inclusion of their first patient into the trial. We are also looking for new partners and are in dialogue with several leading European centers.
Scandinavian Neuro-Oncology Group meeting
April 25-27, 2024 there will an interesting neuro-oncology meeting, and hopefully we can present som preliminary data on the trial there. As of today, we have randomised 22 % of the intended 90. If you see the “useful links” there was recently another promising, yet retrospective, report on the usefulness of supramarginal resection in patients with glioblastoma. Thanks to everyone for your efforts: researchers, caregivers, next-of-kin and patients.
Status of September 2022
Being at the conferences the recent weeks we find it more relevant than ever to perform this trial. The results concerning effectiveness and safety of supramarginal resection are definitely much needed. We have now randomised 15 patients of the 90 patients that we are aiming for. Thanks to collaborators, patients, relatives and funders for supporting us.
Just prior to 2022 we want to thank the enthusiastic colleagues involved in this trial. Thank you for all your efforts during difficult circumstances also in 2021. In addition, we want to send our warmest wishes to all patients and caregivers out there. Happy new year!
Patient recruitment is starting in Finland
Starting in the first week in October, Turku University Hospital will be recruiting participants to the supramarginal trial, and soon after that, Oulu and Kuopio will follow.
Now Vienna has joined the study under supervision of Dr. Georg Widhalm.
We are very thankful for the engagement from Dr. Widhalm and his team, and looking forward to expanding the study during the fall.
Congratulations to Odense (Denmark). The first center to include two or more patients in the supramarginal trial. Well done!
Created with BioRender.com
HAPPY NEW YEAR! BEST WISHES TO ALL PATIENTS AND THEIR RELATIVES, AND TO FUNDERS AND COLLABORATORS IN THIS TRIAL. LET US ACHIEVE PROGRESS, AND THE ONLY WAY TO PROCEED IS TO KEEP UP THE HARD WORK ALSO IN 2021.
Lower-grade glioma
A recent study by Rossi et al, published in Neuro-Oncology, demonstrates an association between supramarginal resection of lower-grade gliomas and improved survival (13/11/2020)
26/06/2020:
We have been somewhat delayed by Covid-19, but now the trial is running and finally we have included our first patient into the trial.
We keep screening to offer the possibility for patients to enter this important trial. A randomised study on this matter is much needed and again emphasised in a recent meta analysis (see Jackson et al under the section “useful links”)
